Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

a redox-active drug that has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress related proteins such as thioredoxin reductase. Its multifunctional mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers. In previously conducted randomized trials, Xcytrin combined with whole brain radiation therapy (WBRT) has been shown to prolong time to neurologic progression in patients with brain metastases from NSCLC.

The target for Xcytrin is the enzyme thioredoxin reductase, which is frequently over expressed in lung cancer cells. This enzyme has been shown to confer to cancer cells characteristics of aggressive tumor growth and resistance to chemotherapy. First line therapy for advanced NSCLC includes combination chemotherapy using drugs such as carboplatin, cisplatin, Gemzar(R) (gemcitabine), taxanes and others. Currently approved agents for second-line treatment of NSCLC include Alimta(R) (pemetrexed), Tarceva(R) (erlotinib) and Taxotere(R) (docetaxel), which have tumor response rates ranging from 4-10%.

Xcytrin, either in combination with Alimta or Taxotere, is now being evaluated in two other ongoing Phase 2 trials as second-line therapy for NSCLC. Interim data from these trials will be presented in late June at the International Lung Cancer Congress Meeting.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/16/2014)... BEDFORD, Massachusetts , 17 settembre 2014 /PRNewswire/ ... ha annunciato oggi il lancio in Europa del ... Il Tomcat è una piattaforma multifunzionale completamente automatizzata, ... tutte le inefficienze ed i rischi di errore ... "L,elevata automazione dello strumento Tomcat di Hologic riduce ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
(Date:9/16/2014)... Ill. , Sept. 16, 2014 ... new director of Business Communications & Advocacy, Urology ... President, Business Communications & Advocacy Margaret Long. In this ... commitment to urology to patient and advocacy organizations, ... teams on key strategic initiatives. Noland,s appointment is ...
Breaking Medicine Technology:Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5Christy Noland to Lead Urology Advocacy and Communications for Astellas 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 Angeldress.co.uk ... kinds of graceful special occasion outfits for worldwide clients. ... officials are thinking of opening the first flagship retail ... fashion industry. Recently, the company has unveiled its new ... promotion. , All its new products are offered ...
(Date:9/17/2014)... In a new video released for ... expert on the condition known as PPP, demonstrates a proven ... or PPP, is a condition that affects mostly uncircumcised men ... affected as well. The condition is characterized by small bumps ... is not a sexually transmitted disease and generally has no ...
(Date:9/17/2014)... Holon Solutions announced today that ... CollaborNet™ Health Information Exchange (HIE) solution ... between Coon Memorial Hospital, a 21-bed critical access ... community. , Coon Memorial is also using ... by physicians to the state’s Quitline tobacco cessation ...
(Date:9/17/2014)... Detroit, MI (PRWEB) September 17, 2014 ... are excited to be of the first in ... Ultherapy Décolletage Treatment, specifically designed to minimize the appearance ... Ultherapy, made waves in 2012 with the first FDA-cleared ... and face, and now they have expanded their brand ...
(Date:9/17/2014)... September 17, 2014 Lee Berman, a ... will be appearing on The Balancing Act® airing on ... episodes. , The segment will premiere on September 19 ... Balancing Act® airing on Lifetime Television®' with show host ... Funding Corp. for over a decade and is the ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 2Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 3Health News:FACE Skincare Medical Wellness Debuts Ultherapy Décolletage Treatment 2Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2
... cancer, found in dogs, wolves and coyotes, can repair its ... according to a new study in the journal Science ... unusual process that helps the cancer survive by stealing tiny ... infected animal, to incorporate as its own. They say this ...
... Amanda Gardner HealthDay Reporter , THURSDAY, Jan. 20 ... very differently depending on what side of the Atlantic ... ("swine") flu still predominated in Britain, where 112 people have ... and some doctors report running out of vaccine, according to ...
... The American Institute of Ultrasound in Medicine (AIUM) announced ... Fetal Echocardiography. The program sets the standard for care ... AIUM guidelines aimed at fostering its safe and effective ... a way for healthcare providers to show that they ...
... notion that feeling good may be good for your health ... article published in Current Directions in Psychological Science , ... existing research on how positive emotions can influence health outcomes ... how we age, however, that determines the quality of our ...
... Journal on Addictions reveals that illicit use of ... American male weightlifters. Additionally, illicit HGH use in this ... performance-enhancing and classical drugs. HGH, once an expensive ... cheaply available for illicit users on the street. ...
... , WEDNESDAY, Jan. 19 (HealthDay News) -- Scientists studying ... critters become resistant to pesticides, and the finding could ... across the United States. "We are starting to ... researcher Omprakash Mittapalli, an assistant professor of entomology at ...
Cached Medicine News:Health News:Contagious cancer thrives in dogs by adopting host's genes 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 3Health News:AIUM announces ultrasound practice accreditation in fetal echocardiography 2Health News:Bedbugs Reveal Their Genetic Secrets in Lab Study 2Health News:Bedbugs Reveal Their Genetic Secrets in Lab Study 3
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
McPherson curved tying forceps is long has curved shafts with tying platform 4 mm, serrated handle and polished finish. Overall length 110 mm....
McPherson straight tying forceps have straight shafts, tying platforms 4 mm, serrated handle, polished finish, overall length 85 mm....
Medicine Products: